1) Really promising reseachs on Alzheimer drug.
2) Atm there are 9.9MILLION new diagnoses of demencia every year(increasing market) this number is 30% more than what the worlds health organization predicted in 2010... hense the undervalue.
3) Increasing Profits
4) EPS at 4,71 higher than what many predicted.
5) Good administration.